Taysha Gene Therapies, Inc. Investment Income, Interest
Taysha Gene Therapies, Inc. (TSHA) reported Investment Income, Interest of $2.33 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2026-08-11
- Taysha Gene Therapies, Inc. investment income, interest for the quarter ending 2026-06-30 was $2.33M, a 25.07% increase year-over-year.
- Taysha Gene Therapies, Inc. investment income, interest for the quarter ending 2026-03-31 was $2.59M, a 95.02% increase year-over-year.
- Taysha Gene Therapies, Inc. investment income, interest for the quarter ending 2025-12-31 was $2.87M, a 68.82% increase year-over-year.
- Taysha Gene Therapies, Inc. investment income, interest for the quarter ending 2025-09-30 was $3.17M, a 50.40% increase year-over-year.
- Taysha Gene Therapies, Inc. investment income, interest for fiscal 2025 was $9.22M, a 32.91% increase from fiscal 2024.
- Taysha Gene Therapies, Inc. investment income, interest for fiscal 2024 was $6.94M, a 94.29% increase from fiscal 2023.
- Taysha Gene Therapies, Inc. investment income, interest for fiscal 2023 was $3.57M.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 6 month | Investment Income, Interest 9 month | Investment Income, Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.33M 10-Q · filed 2026-08-11 | $4.91M 10-Q · filed 2026-08-11 | $7.78M derived: sum of 3 quarters · filed 2026-08-11 | $10.95M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $2.59M 10-Q · filed 2026-05-06 | $5.46M derived: sum of 2 quarters · filed 2026-05-06 | $8.63M derived: sum of 3 quarters · filed 2026-05-06 | $10.48M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $2.87M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $6.04M derived: sum of 2 quarters · filed 2026-03-19 | $7.90M derived: sum of 3 quarters · filed 2026-08-11 | $9.22M 10-K · filed 2026-03-19 |
| 2025-09-30 | $3.17M 10-Q · filed 2025-11-04 | $5.03M derived: sum of 2 quarters · filed 2026-08-11 | $6.35M 10-Q · filed 2025-11-04 | $8.05M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $1.86M 10-Q · filed 2026-08-11 | $3.19M 10-Q · filed 2026-08-11 | $4.88M derived: sum of 3 quarters · filed 2026-08-11 | $6.99M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $1.33M 10-Q · filed 2026-05-06 | $3.03M derived: sum of 2 quarters · filed 2026-05-06 | $5.13M derived: sum of 3 quarters · filed 2026-05-06 | $6.57M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $1.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $3.81M derived: sum of 2 quarters · filed 2026-03-19 | $5.25M derived: sum of 3 quarters · filed 2026-03-19 | $6.94M 10-K · filed 2026-03-19 |
| 2024-09-30 | $2.11M 10-Q · filed 2025-11-04 | $3.55M derived: sum of 2 quarters · filed 2025-11-04 | $5.24M 10-Q · filed 2025-11-04 | $7.16M derived: sum of 4 quarters · filed 2025-11-04 |
| 2024-06-30 | $1.44M 10-Q · filed 2025-08-12 | $3.13M 10-Q · filed 2025-08-12 | $5.05M derived: sum of 3 quarters · filed 2025-08-12 | $6.16M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $1.69M 10-Q · filed 2025-05-15 | $3.61M derived: sum of 2 quarters · filed 2025-05-15 | $4.72M derived: sum of 3 quarters · filed 2025-05-15 | |
| 2023-12-31 | $1.92M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $3.03M derived: sum of 2 quarters · filed 2025-02-26 | $3.57M 10-K · filed 2025-02-26 | |
| 2023-09-30 | $1.11M 10-Q · filed 2024-11-13 | $1.65M 10-Q · filed 2024-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |